Akanda Bolsters Leadership Team to Scale Medical Cannabis Platform Across Europe
August 24th, 2022
News, Top News
Tom Flow Named Chief Operating Officer and Steven George Named Commercial Director
LONDON, August 24, 2022–(BUSINESS WIRE)–International medical cannabis platform company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN) today announced that it has appointed Tom Flow to the role of Chief Operating Officer of Akanda and Managing Director of Holigen, and Steven George to the role of Commercial Director, effective September 1, 2022. The Company believes that these two hires will enhance its leadership direction and boost profitability across the European medical cannabis market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220824005303/en/
The Company announced that it has appointed Tom Flow to the role of Chief Operating Officer of Akanda and Managing Director of Holigen. (Photo: Business Wire)
Mr. Flow is an accomplished global business leader with over 15 years of direct cannabis industry experience with an emphasis on facility design and operations, including multiple large scale EU GMP certified cultivation facilities. He is the co-founder of a number of cannabis companies during this time, namely MedReleaf Corp. which was subsequently sold to Aurora Cannabis (ACB-NASDAQ) in a transaction valued at C$3.2 billion, The Flowr Corporation (“Flowr”) (FLWR-TSXV) where he held executive roles including CEO, COO, President and Managing Partner, and Holigen Limited which the Company acquired from Flowr in May 2022.
Mr. George joins Akanda with extensive experience in the financial services and cannabis sectors. After beginning his career in business development roles within financial services, in 2017, he moved to Portugal to obtain his MBA and started working in the European cannabis industry the following year. In that time, he served as both Iberian Country Manager and European Alliance Manager at Tilray (TLRY-NASDAQ), where his accomplishments included Tilray receiving the first ACM (marketing approval) for a cannabis dried flower in Portugal during his tenure and managing the first medical cannabis exports out of Portugal to Europe and Israel. In July 2021, Mr. George left Tilray and started offering independent advisory services to cannabis clients across the European region.
“Adding proven and elite global cannabis executives like Tom and Steven is an important milestone for Akanda, expanding our capabilities and growing our leadership as we scale. This begins with maximising our combined 10 metric tonne (22,000 lbs) annual cultivation and processing capacity at our EU GMP certified indoor premium cultivation facility in Sintra, Portugal. And, we will also focus on commercially igniting our 180 acre GACP outdoor and greenhouse site at Aljustrel, Portugal, which has over 100 metric tonnes (220,000 lbs) of annual cultivation capacity,” said Tej Virk, Chief Executive Officer at Akanda. “These hires are illustrative of the ongoing work we’re doing to build the best team possible to engage Europe’s rapidly growing cannabis market. Tom is renowned for his operational prowess, having built and scaled indoor premium cannabis cultivation businesses in both Canada and Portugal. Steven, meanwhile, is a commercial pioneer in Europe and will help us accelerate our path to profitability. We have the in-house capability to take a leading position in the existing European medical cannabis market, with an eye to participate in the adult-use market when it opens up.”
Both Mr. Flow and Mr. George will be based in offices at Akanda’s indoor premium cultivation facility in Sintra, Portugal.
About Akanda Corp.
Akanda is an international medical cannabis and wellness platform company seeking to help people lead better lives through improved access to high quality and affordable products. Akanda’s portfolio includes Bophelo Bioscience & Wellness, a GACP qualified cultivation campus in the Kingdom of Lesotho in Southern Africa; Holigen, a Portugal-based cultivator, manufacturer and distributor with a prized EU GMP certified indoor grow facility; and CanMart, a UK-based fully licensed pharmaceutical importer and distributor which supplies pharmacies and clinics within the UK. The Company’s seed-to-patient supply chain also includes partnerships with Cellen Life Sciences’ Leva Clinic, one of the first fully digital pain clinics in the UK, and other leading distributors of medical cannabis in Germany.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220824005303/en/
Matt Chesler, CFA
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.